Source:http://linkedlifedata.com/resource/pubmed/id/19233131
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2009-3-30
|
| pubmed:abstractText |
Human respiratory syncytial virus (RSV) is a serious pediatric pathogen of the lower respiratory tract worldwide. There is currently no clinically approved vaccine against RSV infection. Recently, it has been shown that a replication-deficient first generation adenoviral vector (FGAd), which encodes modified RSV attachment glycoprotein (G), elicits long-term protective immunity against RSV infection in mice. The major problem in developing such a vaccine is that G protein lacks MHC-I-restricted epitopes. However, RSV fusion glycoprotein (F) is a major cytotoxic T-lymphocyte epitope in humans and mice, therefore, an FGAd-encoding F (FGAd-F) was constructed and evaluated for its potential as an RSV vaccine in a murine model. Intranasal (i.n.) immunization with FGAd-F generated serum IgG, bronchoalveolar lavage secretory IgA, and RSV-specific CD8+ T-cell responses in BALB/c mice, with characteristic balanced or mixed Th1/Th2 CD4+ T-cell responses. Serum IgG was significantly elevated after boosting with i.n. FGAd-F. Upon challenge, i.n. immunization with FGAd-F displayed an effective protective role against RSV infection. These results demonstrate FGAd-F is able to induce effective protective immunity and is a promising vaccine regimen against RSV infection.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1090-2104
|
| pubmed:author |
pubmed-author:FuYuanhuiY,
pubmed-author:HeJinshengJ,
pubmed-author:HongTaoT,
pubmed-author:QuJianguoJ,
pubmed-author:SongJingdongJ,
pubmed-author:TangQianQ,
pubmed-author:TouJ TJT,
pubmed-author:UrenCC,
pubmed-author:VigoC BCB,
pubmed-author:WangXiaoboX,
pubmed-author:WebbS LSL,
pubmed-author:WuQiangQ,
pubmed-author:XXX,
pubmed-author:ZhangMeiM,
pubmed-author:ZhangYingY,
pubmed-author:ZhengXianxianX
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
17
|
| pubmed:volume |
381
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
528-32
|
| pubmed:meshHeading |
pubmed-meshheading:19233131-Adenoviridae,
pubmed-meshheading:19233131-Administration, Intranasal,
pubmed-meshheading:19233131-Animals,
pubmed-meshheading:19233131-Antibody Formation,
pubmed-meshheading:19233131-CD8-Positive T-Lymphocytes,
pubmed-meshheading:19233131-Cytotoxicity, Immunologic,
pubmed-meshheading:19233131-Genetic Vectors,
pubmed-meshheading:19233131-Humans,
pubmed-meshheading:19233131-Lung,
pubmed-meshheading:19233131-Mice,
pubmed-meshheading:19233131-Mice, Inbred BALB C,
pubmed-meshheading:19233131-Respiratory Syncytial Virus Infections,
pubmed-meshheading:19233131-Respiratory Syncytial Virus Vaccines,
pubmed-meshheading:19233131-Respiratory Syncytial Viruses,
pubmed-meshheading:19233131-Vaccination,
pubmed-meshheading:19233131-Viral Fusion Proteins,
pubmed-meshheading:19233131-Virus Replication
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
|
| pubmed:affiliation |
Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|